RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors

Contributed by: Business Wire

Logo

Tags

Stem Cells

Biotechnology

Pharmaceutical

Oncology

Health

Infectious Diseases

Genetics

Clinical Trials

RoslinCT

More Like This

RoslinCT Announces Appointment of Jessica Carmen as Chief Commercial Officer

Epsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company Expansion

ViroCell Biologics Appoints Viral Vector Expert as Special Advisor

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

ViroCell Biologics to Host Panel Event at 2024 Cell & Gene Meeting on the Mesa

ViroCell Biologics Expands U.S. Business Development Team With Two New Appointments

ViroCell and Great Ormond Street Hospital Poised to Unlock Clinical Trial ‘Backlog’ Following MHRA Manufacturing Approval

ViroCell Biologics Completes Oversubscribed Financing